Apotea AB (publ)CHIX:APOTES 18 EBITDA Margin % is 8.07% as of Mar. 2026, which is 94% above its 10-year median of 4.15. GuruFocus rates CHIX:APOTES with a GF Score™ of 18/100. The stock has 1 warning sign investors should review. Among 665 Healthcare Providers & Services companies, Apotea AB (publ) ranks worse than 60.45% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Apotea AB (publ)'s EBITDA for the
three
months ended in Mar. 2026 was kr156 Mil. Apotea AB (publ)'s Revenue for the
three
months ended in Mar. 2026 was kr1,937 Mil. Therefore, Apotea AB (publ)'s EBITDA margin for the quarter that ended in Mar. 2026 was 8.07%.
Apotea AB (publ) (CHIX:APOTEs) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Apotea AB (publ) EBITDA Margin % Related Terms
Apotea AB (publ) EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Apotea AB (publ)'s EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apotea AB (publ) EBITDA Margin % Competitor Comparison
For the Pharmaceutical Retailers subindustry, Apotea AB (publ)'s EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apotea AB (publ) EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Apotea AB (publ)'s EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Apotea AB (publ)'s EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apotea AB (publ) (CHIX:APOTES) has a EBITDA Margin % of 8.07% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Apotea AB (publ) and its competitors. This is 94% above median its historical median of 4.15. Over the past decade, Apotea AB (publ)'s EBITDA Margin % has ranged from 2.15 to 6.65. According to the industry distribution chart, Apotea AB (publ) ranks #402 out of 665 companies in the Healthcare Providers & Services industry, placing it in the top 60.5%.
Is Apotea AB (publ)'s EBITDA Margin % too high?
Apotea AB (publ)'s current EBITDA Margin % of 8.07% is 94% above median its 10-year median of 4.15. Over the past 10 years, this metric has ranged from a low of 2.15 to a high of 6.65. The Healthcare Providers & Services industry median EBITDA Margin % is 10.19. Apotea AB (publ)'s value of 8.07% is 20.8% below this industry median. Based on the distribution chart, Apotea AB (publ) ranks #402 out of 665 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Apotea AB (publ) has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Apotea AB (publ)'s EBITDA Margin % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Apotea AB (publ) ranks #402 out of 665 companies for EBITDA Margin %. This places Apotea AB (publ) in the lower half of its industry. The industry median EBITDA Margin % is 10.19. Apotea AB (publ)'s value of 8.07% is 20.8% below this benchmark. Historically, Apotea AB (publ)'s own EBITDA Margin % has ranged from 2.15 to 6.65 over the past decade. While the company's 10-year median is 4.15 vs. the industry median of 10.19, Apotea AB (publ) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.19, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apotea AB (publ)'s current EBITDA Margin % of 8.07% is 20.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Apotea AB (publ) and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apotea AB (publ)'s current EBITDA Margin % is 8.07%, which is 94% above median its own 10-year median of 4.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apotea AB (publ) stock overvalued right now?
Apotea AB (publ) (CHIX:APOTES) has a current EBITDA Margin % of 8.07%. The current EBITDA Margin % is 8.07%, which is 94% above median its 10-year median of 4.15 and 20.8% below the Healthcare Providers & Services industry median of 10.19. Apotea AB (publ)'s overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Apotea AB (publ) (CHIX:APOTES), the current EBITDA Margin % is 8.07% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Apotea AB (publ) is engaged in the online pharmacy with fast deliveries, good prices and a large selection. Its vision is to be tomorrow's pharmacy by constantly facilitating and simplifying for the customer.
18GF Score
Get the complete analysis for CHIX:APOTES
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:APOTES has been successfully added to your 
